About
53
Publications
3,276
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
428
Citations
Publications
Publications (53)
Variances in global access to drugs and treatment practices make it challenging to understand the benefit of contemporary therapies in patients with relapsed and refractory (R/R) mature T-cell and NK-cell lymphomas (MTCL and MNKCL). We conducted an international retrospective cohort study of 925 patients with R/R MTCL and MNKCL. In PTCL-NOS and ALK...
Peripheral T‐cell lymphomas (PTCLs) are a heterogeneous group of haematological cancers with generally poor clinical outcomes. However, a subset of patients experience durable disease control, and little is known regarding long‐term outcomes. The International T‐cell Lymphoma Project (ITCLP) is the largest prospectively collected cohort of patients...
We report the outcome of 563 cases of newly diagnosed lymphoma registered in 2019–2021, including 176 cases (31.2%) of Hodgkin lymphoma (HL), 130 (23.1%) of diffuse large B‐cell lymphoma (DLBCL), 28 (5%) of follicular lymphoma (FL), 16 (2.9%) of mantle cell lymphoma (MCL) and 20 (3.5%) of peripheral T‐cell lymphoma (PTCL). After a median follow‐up...
We conducted a post hoc analysis of the FOLL12 trial to determine the impact of different initial immunochemotherapy (ICT) regimens on patient outcomes. Patients were selected from the FOLL12 trial, which included adults with stage II-IV follicular lymphoma (FL) grade 1-3a and high tumor burden. Patients were randomized 1:1 to receive either standa...
The natural history of limited-stage peripheral T-cell lymphomas (PTCLs) remains poorly defined. We investigated outcomes and prognostic variables in patients registered in the T-Cell Project (TCP)(NCT01142674) to develop a model to predict overall survival (OS) for the common nodal PTCL subtypes (PTCL-NOS, AITL, ALCL). The model was validated in a...
The Ukrainian Lymphoma Registry (ULR) was established in 2019 with the aim of monitoring the quality of diagnosis, staging, and treatment of lymphoma in Ukraine. Between September 2019 and October 2021, 546 patients with newly diagnosed lymphoma were prospectively registered. All cases were diagnosed according to the 2016 updated WHO lymphoma class...
ABSTRACT In 2014, a committee of clinicians and nuclear medicine experts issued the recommendations for lymphoma staging and restaging based on the use of positron emission tomography/computed tomography (PET/CT). These recommendations were immediately adopted in the Western countries and have become part of the routine clinical use. In contrast, t...
Simple Summary
The multidisciplinary team of Fondazione Italiana Linfomi researchers conducted a systematic review of the literature (PubMed, EMBASE, Cochrane database) regarding incidence, comparison between systemic therapies and radiotherapy (RT) (old versus modern techniques), and the better monitoring of long-term classical Hodgkin lymphoma an...
PURPOSE
We compared 2 years of rituximab maintenance (RM) with a response-adapted postinduction approach in patients with follicular lymphoma who responded to induction immunochemotherapy.
METHODS
We randomly assigned treatment-naïve, advanced-stage, high-tumor burden follicular lymphoma patients to receive standard RM or a response-adapted postin...
Context
It is estimated that cancer survivors number more than 16 million in the USA and 12 million in Europe, and rapid population growth is predicted. We still need more information to set up an evidence-based follow-up and preventive strategy for lymphoma survivors.
Objective
i) Evaluate the incidence of long-term sequelae due to treatments for...
Context
Scarce data on clinical features and treatment outcomes of elderly patients is presented in clinical practice. The outcomes of elderly patients are worse, especially with aggressive lymphoma types. The conventional CHOP-based chemotherapy is a standard frontline treatment for peripheral T-cell lymphomas (PTCLs).
Objective
In this report, w...
Primary renal lymphoma (PRL) is a rare form of non-Hodgkin’s lymphoma (NHL) restricted to and primarily involving one or both kidneys, with no lymph node extension. It accounts for <1% of extranodal lymphomas, and descriptions in the literature are limited. Here, we describe an unprecedented case of bilateral PRL in a 44-year-old woman with Turner...
Peripheral T‐cell lymphomas (PTCLs) are a rare, heterogeneous group of hematological malignancies with extremely poor prognosis for almost all subtypes. The diverse clinicopathological features of PTCLs make accurate diagnosis, prognosis, and choice of optimal treatment strategies difficult. Moreover, the best therapeutic algorithms are still under...
Angioimmunoblastic T-cell lymphoma (AITL) is a unique subtype of peripheral T-cell lymphoma (PTCL) with distinct clinicopathologic features and poor prognosis. We performed a subset analysis of 282 patients with AITL enrolled between 2006 and 2018 in the international prospective T-cell Project (NCT01142674). The primary and secondary endpoints wer...
Angioimmunoblastic T-cell lymphoma (AITL) is a unique subtype of peripheral T-cell lymphoma (PTCL) with distinct clinicopathologic features and poor prognosis. We performed a subset analysis of 282 patients with AITL enrolled between 2006 and 2018 in the international prospective T-cell Project (NCT01142674). The primary and secondary endpoints wer...
The detection of gastrointestinal (GI) involvement in Mantle Cell Lymphoma is often underestimated and may have an impact on outcome and clinical management. We aimed to evaluate whether baseline 18F-FDG PET/CT presents comparable results to endoscopic biopsy in the diagnosis of GI localizations. In our retrospective cohort of 79 patients, sensitiv...
Anaplastic lymphoma kinase–negative anaplastic large cell lymphoma (ALK– ALCL) is an aggressive neoplasm of T-cell/null-cell lineage. The T-Cell Project is a global prospective cohort study that consecutively enrolled patients newly diagnosed with peripheral T-cell lymphoma, registered through a centralized computer database between September 2006...
Paget disease is a complex disorder that can be identified in the breast (mammary Paget disease) or in other locations (extramammary Paget's disease) such as ano-genital skin (Paget disease of the vulva -PVD). This condition is associated with low mortality, but a late diagnosis and recurrence can negatively impact the prognosis. Therefore, the mai...
Peripheral T‐cell lymphomas (PTCLs) comprise a heterogeneous group of neoplasms that are derived from post‐thymic lymphoid cells at different stages of differentiation with diverse morphological patterns, phenotypes, and clinical presentation. To overcome the intrinsic limitations of population‐based cancer registries and retrospective studies, the...
Introduction:
In recent years, the positron emission tomography combined with computed tomography (PET/CT) has changed and the treatment approaches in Hodgkins lymphoma (HL) patients have entirely improved. The main idea in several studies is the use of PET/CT and the International Prognostic Score (IPS) protocols in identification of patients wit...
Background
Angioimmunoblastic T-cell lymphoma (AITL) is a rare and unique subtype of peripheral T-cell lymphoma (PTCL) with distinct clinicopathologic features. Clinical presentation is varied with an aggressive course and dismal outcomes. Curative treatment modalities in AITLs are still an unmet need.
Aims
In this study, we aimed to advance our u...
Background: Paget disease is a rare neoplasia, most commonly diagnosed in postmenopausal women and which can be identified in the breast (mammary Paget disease) or in other locations (extramammary Paget’s disease) such as ano-genital skin (Paget disease of the vulva -PVD). This condition is associated with low mortality, but a late diagnosis and re...
Background
Extranodal natural killer (NK) T-cell lymphoma (ENKTL) is a unique clinicopathological entity, typically associated with poor survival outcomes. Most published data have come from east Asian study groups, with little information available from international cohorts. The effects of treatment advances on routine clinical practice across c...
Background: PET-CT has completely changed and improved treatment
approaches in patients with Hodgkin Lymphoma (HL) for the last years. Recent studies are evaluated predictive role PET for survival rate. The major idea is to identify patients from a high-risk group who can have early relapse/refractory disease using iPET and IPS to guide the choice...
Background: DLBCL is the most common subtype of NHL in adults. The efficacy of chemotherapy in DLBCL patients has significantly increased in the last 10 years. Growing evidence has shown genetic and environmental factors are involved in the etiology and prognosis of DLBCL. Genetic polymorphisms can influence the individual
susceptibility and clinic...
Background: Nowadays, there are different guidelines in diagnostics and PET-guided treatment of lymphomas. But questions about benefits and predictive role of PET-CT in pts with early-stage Hodgkin lymphoma (HL) still remain debatable. Here we report results of Ukrainian multicenter retrospective study about the role of PET-CT in earlystage HL pts....
Background:
Histological transformation of follicular lymphoma to aggressive lymphoma is a serious event with a substantial effect on patient outcome. The aim of the Aristotle study was to assess the effect of rituximab on the risk of histological transformation and its outcome.
Methods:
11 cooperative groups or institutions across Europe contri...
Background: Nowadays, patients with Hodgkin’s lymphoma (HL) have a high cure rate. However, approximately 20% pts have relapse or progressive disease. The main histological feature in HL is presence by Hodgkin Reed-Sternberg (HRS) cells. HRS cells produce a diversity of cytokines and chemokines. There is still a limited information of prognostic ro...
Background: Indoleamine 2,3-dioxygenase (IDO) is an inducible enzyme that catalyzes the initial and rate-limiting step in tryptophan along the kynurenine pathway. IDO is a key factor maintaining immune tolerance and expression and it correlates with poor clinical outcome in different types of cancer and hematological malignancies. It also plays a r...
Background. Indoleamine 2,3-dioxygenase (IDO) catalyzes the ratelimiting step in the metabolism of tryptophan along the kynurenine pathway. IDO is a key factor maintaining immune tolerance and expression
correlates with poor clinical outcome in different types of cancer and hematological malignancies. Nowadays, not enough attempts have been made to...
Background: Indoleamine 2,3-dioxygenase (IDO) is an intracellular enzyme that mediates the metabolism of the essential amino acid L-tryptophan into immunosuppressive metabolites, such as kynurenine and 3-hydroxyanthranilic acid. IDO is a key factor maintaining immune tolerance, and is overexpressed in several human cancers: prostate, breast, brain,...
